NO991191L - Tienotriazolodiazepinforbindelser og farmas°ytisk anvendelse derav - Google Patents

Tienotriazolodiazepinforbindelser og farmas°ytisk anvendelse derav

Info

Publication number
NO991191L
NO991191L NO991191A NO991191A NO991191L NO 991191 L NO991191 L NO 991191L NO 991191 A NO991191 A NO 991191A NO 991191 A NO991191 A NO 991191A NO 991191 L NO991191 L NO 991191L
Authority
NO
Norway
Prior art keywords
compound
inventive compound
useful
pharmaceutically acceptable
pharmaceutical
Prior art date
Application number
NO991191A
Other languages
English (en)
Other versions
NO323892B1 (no
NO991191D0 (no
Inventor
Hiroyuki Sueoka
Haruhito Kobayashi
Syuji Ehara
Hirotsugu Komatsu
Original Assignee
Yoshitomi Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical filed Critical Yoshitomi Pharmaceutical
Publication of NO991191D0 publication Critical patent/NO991191D0/no
Publication of NO991191L publication Critical patent/NO991191L/no
Publication of NO323892B1 publication Critical patent/NO323892B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19991191A 1996-09-13 1999-03-11 Tienotriazolodiazepinforbindelser og medikamenter omfattende disse NO323892B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24379396 1996-09-13
PCT/JP1997/002817 WO1998011111A1 (fr) 1996-09-13 1997-08-11 Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales

Publications (3)

Publication Number Publication Date
NO991191D0 NO991191D0 (no) 1999-03-11
NO991191L true NO991191L (no) 1999-04-23
NO323892B1 NO323892B1 (no) 2007-07-16

Family

ID=17109041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991191A NO323892B1 (no) 1996-09-13 1999-03-11 Tienotriazolodiazepinforbindelser og medikamenter omfattende disse

Country Status (15)

Country Link
EP (1) EP0989131B1 (no)
JP (1) JP3094453B2 (no)
KR (1) KR100338144B1 (no)
CN (1) CN1109037C (no)
AT (1) ATE227727T1 (no)
AU (1) AU716490B2 (no)
CA (1) CA2265645C (no)
DE (1) DE69717160T2 (no)
DK (1) DK0989131T3 (no)
EA (1) EA001732B1 (no)
ES (1) ES2182108T3 (no)
HK (1) HK1023571A1 (no)
NO (1) NO323892B1 (no)
PT (1) PT989131E (no)
WO (1) WO1998011111A1 (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412776C (en) * 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
SI2902030T1 (sl) 2010-05-14 2017-01-31 Dana-Farber Cancer Institute, Inc. Tienotriazolodiazepinske spojine za zdravljenje neoplazije
JP6022442B2 (ja) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 男性用避妊組成物および使用方法
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP5989229B2 (ja) 2012-04-20 2016-09-07 アッヴィ・インコーポレイテッド イソインドロン誘導体
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
IN2014DN11269A (no) * 2012-06-25 2015-10-09 Oncoethix Sa
EA201590356A1 (ru) 2012-08-16 2015-07-30 Байер Фарма Акциенгезельшафт 2,3-бензодиазепины
EP2900672B1 (de) 2012-09-28 2017-02-22 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
MX2015003771A (es) * 2012-09-28 2016-03-04 Oncoethix Gmbh Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina.
CA2903463A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
WO2014159392A1 (en) * 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
EP3027194A1 (en) * 2013-08-01 2016-06-08 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
CN103694253A (zh) * 2013-11-04 2014-04-02 湖南华腾制药有限公司 一种噻吩并三唑并[4,3-a][1,4]二氮杂卓类化合物的制备方法
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN105940005A (zh) 2014-01-31 2016-09-14 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
RU2017104898A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Дигидроптеридиноновые производные и их применения
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
CR20170219A (es) 2014-10-27 2017-08-14 Tensha Therapeutics Inc Inhibidores del bromodominio
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
MX2018003030A (es) 2015-09-11 2018-04-11 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas.
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
ES2882066T3 (es) 2016-02-15 2021-12-01 Univ Michigan Regents 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
RU2752677C2 (ru) 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка вет
CR20180541A (es) 2016-04-15 2019-07-04 Abbvie Inc Inhibidores de bromodominios
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3858837A1 (en) 2016-09-13 2021-08-04 The Regents of The University of Michigan Fused 1,4-diazepines as bet protein degraders
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CA3041949A1 (en) 2016-12-16 2018-06-21 F. Hoffmann-La Roche Ag Process for the manufacture of diazepine derivatives
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CA3064845A1 (en) * 2017-05-31 2018-12-06 Ayumi Pharmaceutical Corporation 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
CA3102178A1 (en) 2018-06-13 2019-12-19 Dybly Ag Preparation of condensed triazepine derivatives and their use as bet inhibitors
JP6744516B2 (ja) 2018-07-04 2020-08-19 田辺三菱製薬株式会社 Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途
CN113631559B (zh) * 2019-03-07 2023-05-23 南京明德新药研发有限公司 同时具有BET Bromodomain蛋白抑制和PD-L1基因调控作用的化合物
US20230146717A1 (en) 2020-02-06 2023-05-11 Mitsubishi Tanabe Pharma Corporation Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
WO2022048685A1 (zh) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 苯并四氢呋喃肟类化合物的晶型及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA87377B (en) * 1986-01-21 1988-09-28 Boehringer Ingelheim Int New thieno-1,4-diazepine
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
CA2020806A1 (en) * 1989-07-12 1991-01-13 Karl-Heinz Weber Thienodiazepine derivatives
WO1994006801A1 (en) * 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
DE4027470A1 (de) * 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
DK0656361T3 (da) * 1991-12-11 2000-07-24 Yoshitomi Pharmaceutical Lægemiddel til behandling af autoimmune sygdomme
JP3215489B2 (ja) * 1992-04-23 2001-10-09 日本電信電話株式会社 燃料電池排熱利用システムとその制御方法
WO1994006802A1 (en) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
WO1994022872A1 (en) * 1993-03-30 1994-10-13 Yoshitomi Pharmaceutical Industries, Ltd. Cell adhesion inhibitor and thienotriazolodiazepine compound
JP3633008B2 (ja) * 1993-11-15 2005-03-30 三菱ウェルファーマ株式会社 チエノトリアゾロジアゼピン化合物
JPH0879471A (ja) * 1994-09-01 1996-03-22 Konica Corp 画像形成装置

Also Published As

Publication number Publication date
CN1109037C (zh) 2003-05-21
CN1237180A (zh) 1999-12-01
KR20000036057A (ko) 2000-06-26
NO323892B1 (no) 2007-07-16
AU716490B2 (en) 2000-02-24
DE69717160T2 (de) 2003-05-08
PT989131E (pt) 2003-03-31
DK0989131T3 (da) 2003-03-03
EA199900287A1 (ru) 1999-08-26
CA2265645A1 (en) 1998-03-19
WO1998011111A1 (fr) 1998-03-19
EP0989131A1 (en) 2000-03-29
KR100338144B1 (ko) 2002-05-24
CA2265645C (en) 2007-01-23
ES2182108T3 (es) 2003-03-01
NO991191D0 (no) 1999-03-11
EP0989131A4 (en) 2000-03-29
JP3094453B2 (ja) 2000-10-03
EA001732B1 (ru) 2001-08-27
DE69717160D1 (de) 2002-12-19
EP0989131B1 (en) 2002-11-13
ATE227727T1 (de) 2002-11-15
AU3786097A (en) 1998-04-02
HK1023571A1 (en) 2000-09-15

Similar Documents

Publication Publication Date Title
NO991191D0 (no) Tienotriazolodiazepinforbindelser og farmas°ytisk anvendelse derav
AR015768A1 (es) DERIVADOS DE IMIDAZO PIRIDINA QUE INHIBEN LA SECRECIoN DE ÁCIDO GÁSTRICO, COMPOSICIoN FARMACÉUTICA, PROCEDIMIENTOS PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA, USO DE DICHOS DERIVADOS PARA PREPARAR MEDICAMENTOS Y COMPUESTOS INTERMEDIARIOS uTILES EN EL PROCEDIMIENTO PARA LA PREPARACIoN DE DICHOS DE
NO171785C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater
DK0770079T3 (da) Heterobicykliske derivater
BR9807457A (pt) Composto, sal de hidrocloreto, formulação farmacêutica, uso de um composto, e, processos para a preparação de um composto, para a inibição da secreção de ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinais e para o tratamento ou profilaxia de condições que envolvem infecção por helicobacter pylori da mucosa gástrica humana.
IL165181A0 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
FI894693A0 (fi) Menetelmä valmistaa farmaseuttisesti arvokasta imidatsoliinijohdannaista
FI102964B1 (fi) Terapeuttisia yhdisteitä
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
NO923200L (no) Piperidin-derivater
ES8704932A1 (es) Procedimiento para preparar un derivado de acido quinoloncarboxilico
DK451687A (da) 2-guanidino-4-arylthiazol-forbindelser og farmaceutiske praeparater indeholdende disse
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
ATE109003T1 (de) Therapeutisches mittel gegen pollakiurie, harndrang oder harninkontinenz, das alpha-phenyl- alpha-pyridylalkan-carbonsäurederivate enthält.
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DK0638587T3 (da) Salmyciner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
HK34095A (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
IT1107771B (it) Composizione farmaceutica antiartritica ed antiinfiammatoria
TH13247EX (th) อนุพันธ์เททราไฮโดรฟิร์โรโล [1,2-a]ไพราชีน-4-สไพโร-3'-พิริโรลิดีน กรรมวิธีสำหรับเตรียมสารนั้นและสารผสมในทางเภสัชกรรมซึ่งมีสารนั้น
ES8103107A1 (es) Un procedimiento para la preparacion de un complejo de cinc.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MITSUBISHI TANABE PHARMA CORP, JP

MK1K Patent expired